title: The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
abstract: OBJECTIVE
  Overactive bladder symptom score (OABSS) was developed by a Japanese urologist and is widely used in Asian countries. The aim of this study was to develop and validate a Chinese OABSS for assessing overactive bladder (OAB) and treatment outcome after solifenacin.
  
  
  METHODS
  The Chinese OABSS was developed by linguistic validation of the original version. Its reliability and validity, and correlations with a three-day bladder diary were tested. Patients answered the Chinese OABSS at enrollment and repeated the questionnaire after a non-treatment period of 2 weeks, and at 4 and 12 weeks after solifenacin (5mg/day). Patients also completed a three-day bladder diary and forms including patient perception of bladder condition, International Prostatic Symptom Score and quality of life index at each study visit (for a total of four visits). An analysis was conducted to evaluate the reliability and validity of the Chinese OABSS and the correlations with a three-day bladder diary and a patient perception of bladder condition, respectively.
  
  
  RESULTS
  A total of 60 patients with OAB, including 31 OAB wet and 29 OAB dry, were enrolled. The test-retest reliability of Chinese OABSS was moderate to good with weighted kappa coefficients of 0.515-0.721 for each symptom score and 0.610 for total symptom score. Forty-eight (80%) patients completed the responsiveness study and were followed-up at all time points. Patients' OAB symptoms improved significantly from baseline to 3 months after solifenacin treatment. The changes in OABSS decreased gradually with time within the three months of solifenacin treatment.
  
  
  CONCLUSIONS
  The Chinese OABSS has been validated as a reliable instrument for assessing OAB. Solifenacin 5mg once daily improved urgency and other symptoms of OAB including frequency, urge incontinence, OABSS and International Prostatic Symptom Score. The adverse effects were acceptable and became less significant with time in the three months of treatment.
authors.affiliation: Department of Urology, China Medical University Hospital, Taichung, Taiwan.
authors.forename: Eric Chieh-Lung
authors.initials: EC
authors.lastname: Chou
authors.affiliation: Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Obstetrics and Gynecology, Chung Shan Medical University School of Medicine, Taichung, Taiwan.
authors.forename: Man-Jung
authors.initials: MJ
authors.lastname: Hung
authors.affiliation: Department of Urology, Lo-Sheng Sanatorium, Department of Health, New Taipei City, Taiwan.
authors.forename: Ta-Wei
authors.initials: TW
authors.lastname: Yen
authors.affiliation: Division of Urology, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Kaohsiung, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
authors.forename: Yao-Chi
authors.initials: YC
authors.lastname: Chuang
authors.affiliation: Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
authors.forename: En
authors.initials: E
authors.lastname: Meng
authors.affiliation: Division of Urology, Department of Surgery, Chang Gung Memorial Hospital-Linkou, College of Medicine, Chang Gang University, Taoyuan, Taiwan.
authors.forename: Shih-Tsung
authors.initials: ST
authors.lastname: Huang
authors.affiliation: Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan. Electronic address: hck@tzuchi.com.tw.
authors.forename: Hann-Chorng
authors.initials: HC
authors.lastname: Kuo
mesh_terms: D000328:Adult; D000368:Aged; D002681:China; D005260:Female; D006801:Humans; D007802:Language; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D011788:Quality of Life; D015203:Reproducibility of Results; D000069464:Solifenacin Succinate / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000175:diagnosis* / Q000188:drug therapy*; D053202:Urinary Incontinence, Urge / Q000188:drug therapy*
chemical_list: D018727:Muscarinic Antagonists; D000069464:Solifenacin Succinate
keywords: antimuscarinics; detrusor overactivity; incontinence; overactive bladder; symptom score; voiding diary